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Summary Mutations in the BRCA1/BRCA2 genes account for varying proportions of breast cancer families studied, and demonstrate
considerable variation in mutational spectra coincident with ethnic and geographical diversity. We have screened for mutations in 17 families
from Wales with two or more cases of breast cancer under age 50 and/or ovarian cancer. Eight out of 17 (47%) families had demonstrable
mutations. Six out of 17 (35%) carried BRCA1 mutations and 2 out of 17 (12%) carried BRCA2mutations. Two recurrent mutations in BRCA1
were identified, which appear to represent founder mutations in this population. These data support the existence of additional breast and
ovarian cancer susceptibility genes.
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Two genes, BRCAJ and BRCA2, have been identified as being
causative in familial breast/ovarian cancer (Miki et al, 1994;
Wooster et al, 1995). Carriers ofgermline mutations in these genes
are at increased risk of developing breast and ovarian cancers.
Analysis ofBRCA1/BRCA2 in high-risk families has demonstrated
considerable heterogeneity in inactivating mutations, with a lower
proportion offamilies attributable to mutations in either gene than
had previously been predicted by statistical analyses (Castilla et al,
1994; Phelan et al, 1996; Serova et al, 1997). We have screened
affected individuals from 17 high-risk Welsh breast and
breast/ovarian cancer families for mutations in both BRCAJ and
BRCA2 to determine the proportion of families attributable to
defects in these genes. Recent experience with recurrent BRCAJ
and BRCA2 mutations in the Ashkenazi Jewish and Icelandic
populations (Neuhausen et al, 1996a; Offit et al, 1996; Thorlacius
et al, 1996), coupled with studies of Welsh cystic fibrosis patients
(Ashley, 1986; Cheadle et al, 1993; Lucotte and Hazout, 1995),
suggests that screening for common genetic alterations in patients
with familial breast and ovarian cancer in the Welsh population
may prove a productive approach to the study of susceptibility in
this group.
PATIENTS AND METHODS
Seventeen families with two or more individuals diagnosed with
breast cancer before age 50 years and/or ovarian cancer were
selected under informed consent from patients attending the
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Department of Medical Genetics at the University Hospital of
Wales, Cardiff, UK. All families were resident in Wales, with all
obviously non-UK names excluded. Pedigrees were obtained by a
registered nurse in a face-to-face interview with the patient.
Verification of diagnosis was carried out by patient chart and
pathology report review wherever possible. All families fulfilling
inclusion criteria, who agreed to participate, were reported in the
study. All coding exons for BRCAI and BRCA2 were analysed by
single-stranded conformation analysis (SSCA) in fragments of
200-300 bp (Miki et al, 1994; Lancaster et al, 1996a). Genomic
DNA was amplified by the polymerase chain reaction (PCR) in a
Perkin-Elmer 9600 Thermocycler (Perkin-Elmer, CA, USA).
Reaction products were then electrophoresed on 0.5 x MDE
(FMC, ME, USA) gels, dried and autoradiographed. Additionally,
BRCAI exon 11 and BRCA2 exons 10, 11 and 27 were screened
for frameshift and nonsense mutations (producing premature stop
codons) using the protein truncation test (PTT) (Lancaster et al,
1996a, 1996b). Exon 11 (BRCAJ) and exons 10 and 27 (BRCA2)
were amplified by PCR in one fragment, and exon 11 (BRCA2) in
two fragments, in the presence offorward primers containing a T7
promoter and transcription/translation initiation sequence (primer
sequences available from jmlanc@acpub.duke.edu). The PCR
product was then subjected to an in vitro transcription/translation
reaction (Promega, Madison, WI, USA), electrophoresed on a
10-20% sodium dodecyl sulphate (SDS)-polyacrylamide Ready-
Gel (Biorad, Malvem, PA, USA), fixed, dried and autoradi-
ographed. Sequencing templates were produced for samples
showing aberrant mobility on SSCA or PTT and sequenced using
a PRISM DyeDeoxy Terminator Cycle Sequencing Kit and an
ABI PRIZM 377 Automated Fluorescent Sequencer (Applied
BioSystems, CA, USA), according to manufacturer's instructions.
Genotyping was carried out using fluorescent dye-labelled primer
pairs analysed on the ABI377 with the Genescan software
package. Sequences of primers are available from the Genome
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Table 1 Families screened for BRCA1 and BRCA2 mutations
Family Mutation Effect BrCa BrCa OvCa Comments/other
cases < 50 years cases cases cancers
(n) (n) (n)
Families positive for BRCA1 mutations
CDF2 4184deITCAA terl364 2 2 0
CDF7 4184deITCAA ter 364 4 4 0 Two bilateral BrCa cases
CDF10 2011insT ter615 3 3 0 One bilateral BrCa case
'abdominal' cancer
CDF13 2594delC ter845 1 1 3
CDF128 2594delC ter845 6 4 0 Uterus, testicle, lung
CDF209 1997del4 ter6l0 2 2 0
Families positive for BRCA2 mutations
CDF107 4075delGT ter 284 3 2 0 BrCa maternal and paternal sides,
Pancreas, prostate, cervix
CDF325 6287del4 ter2047 4 2 0
Families screened negative for mutations
CDF1 4 4 0 One bilateral BrCa case
CDF5 4 3 1 One dual primary BrCa/OvCa
CDF8 4 2 0
CDF11 5 2 0
CDF12 1 1 3 All affected < 40 years
CDF16 1 1 1 OvCa age 48 years
CDF65 7 4 0
CDF85 4 2 2 Cancer cervix, stomach (40s)
CDF312 4 2 0 Cancer larynx
ter, termination codon; BrCa, breast cancer; OvCa, ovarian cancer; del, deletion. Readers should refer to the Breast Cancer Information Core (BIC) for full,
up-to-date mutation spectra in both genes.
Data Base (http:gdbwww.gdb.org/gdb/gdbtop.html). A database of
updated BRCAI and BRCA2 mutations is catalogued by the Breast
Cancer Information Core Database at the BIC web site
(http://www.nchgr.nih.gov/dir/lab_transfer/bic/).
RESULTS
Inactivating mutations were identified in 8 out of 17 (47%)
families - six in BRCAJ (35%) and two in BRCA2 (12%) (Table
1). All mutations produced frameshifts that were predicted to
result in premature termination of protein synthesis. The average
age at diagnosis of breast cancer in eight families carrying muta-
tions was 40.7 years, compared with an average age of48.6 years
in nine families without mutations (not statistically significant).
Seven out of eight (87%) families carrying mutations contained a
very early onset case ofbreast cancer (< 40 years), compared with
four out of nine (44%) families without mutations. Of 13 site-
specific breast cancer families (no ovarian cancer), five (38%)
contained BRCAI mutations and two (15%) BRCA2 mutations. Of
the five breast/ovarian families in the study, only one was found to
be segregating a BRCAJ mutation. No BRCA2 mutations were
observed in breast/ovarian families. Two recurrent BRCAJ muta-
tions were found, 4184de14 and 2594delC. DNA samples from the
recurrent mutation carriers were genotyped for a series of poly-
morphic microsatellite markers both in the BRCAJ gene
(D17S855, D17S1322) and flanking (D17S1185, D17S1320,
D17S1325) the BRCAJ gene. Genotyping results for the recurrent
mutation chromosomes are given in Table 2 and discussed below.
DISCUSSION
In this study, 17 Welsh families with apparent hereditary
breast/ovarian cancer were studied for BRCAI/BRCA2 mutations.
Table 2 Haplotypes of common BRCA1 mutations in Wales
Family (mutation)
CDF2 CDF7 CDF13 CDF128
(4184del4 - (4184del4 - (2594delC - (2594delC -
Marker BRCA1) BRCA1) BRCA1) BRCA1)
D17S1185 ND ND 214 214
D17S1320 170 170 172/176 172/176
D17S855 157 157 149 149
D17S1322 121 121 121/127 121/127
D17S1325 196 196 214 214
Alleles given in basepairs. Markers are in centromeric to telomeric order.
D17S855 and D17S1322 are both intragenic to BRCA1. ND, not done.
The results show that, overall, only approximately half of these
families were found to be segregating either a BRCAJ or BRCA2
mutation. This proportion, although lower than that predicted by
statistical analysis of a cohort of families collected for the linkage
analysis, is in agreement with that observed in several other
studies. Interestingly, recurrent mutations were observed in halfof
the families with mutations, all of whom appear to be unrelated.
Families CDF2 and CDF7 were found to have aBRCAJ 4184de14
mutation, whereas families CDF13 and CDF128 were found to
have a BRCAJ 2594delC mutation. DNA samples from the recur-
rent mutation carriers were genotyped for a series ofpolymorphic
microsatellite markers in and flanking BRCAJ to assess haplotype
sharing which would be indicative of common founder effects for
these two mutations (Table 2). A common 157-bp allele at the
D17S855 intragenic marker was found in the 4184de14 families.
This D17S855 allele was not detected in typing 94 chromosomes
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from unaffected Welsh control subjects and appears to be quite rare
in this population (unpublished results). Other studies have also
reported a Dl7S855 157-bp allele in association with the 4184de14
mutation (Neuhausen et al, 1996). However, in those families, a
11 8-bp allele at the adjacent intragenic marker D17S1322 has been
reported, whereas CDF2 and CDF7 share a 121-bp D17S1322
allele in disequilibrium with the D17S855 allele. The 4184de14
mutation has been reported 14 times in individuals of various
ethnic backgrounds, and appears to be segregating on at least two
different haplotypes to which our data from Wales adds a third
(Neuhausen et al, 1996b; Szabo and King, 1997). Two other
families, CDF13 and CDF128, were found to be carrying a
common 2594delC BRCAJ mutation. Genotyping revealed a
common haplotype for this mutation as well. An additional marker
centromeric to BRCAI, D17S1185, was also typed to confirm
allele sharing proximal to the ambiguous genotype at Dl7S1320.
This mutation has also been reported frequently in Sweden and
Denmark (Johannsson et al, 1996; Hakansson et al, 1997), with
those families reported to share a common allele of D17S855, and
has also been reported once in a family from the south of England
(Campbell et al, 1997). As is the case for the BRCAJ 4184de14
mutation, data for the BRCAJ 2594delC mutation indicates that it
is also probably a recurrent founder mutation in the Welsh popula-
tion. Full genealogical tracing is ongoing for all families with
recurrent mutations. Additionally, we hope to obtain DNA from
other members offamily CDF128 to assess BRCAI mutation status
in individuals affected with uterine, lung and testicular carcinoma.
This study suggests that screening for the two recurrent BRCAJ
mutations described here may be a useful first step in assessing
Welsh hereditary breast/ovarian cancer families.
The mutation detection rate in this cohort compares favourably
with families ascertained in other studies (Phelan et al, 1996; Szabo
and King, 1997). The proportion of breast cancer families attribut-
able to BRCAJ and BRCA2 mutations in this cohort is roughly
similar to that described elsewhere in Britain (Szabo and King,
1997). However, the finding ofonly one offive breast/ovarian fami-
lies with BRCA] mutations is less than has been reported elsewhere
(Narod et al, 1995). Additionally, we failed to detect any instances of
the 6503delTT mutation in BRCA2 that has been seen frequently in
British families (Mazoyer et al, 1996). These data support the obser-
vation that although the overall contribution of BRCAJ/BRCA2 to
familial breast cancer may be the same among study groups, the
distribution of mutations is quite variable with respect to ethnogeo-
graphical differences. BRCA] mutation detection sensitivity using
SSCA alone is approximately 80% (Lancaster et al, 1997), and our
detection rate in this study is probably increased by the additional use
oftheprotein truncation test (PTT). However, even ifSSCA and PTT
together fail to identify 15% of mutations, our data still provide
support for the view that a significant proportion of familial
breast/ovarian cancer (approximately 35-53%) is not due to muta-
tions in either BRCAJ or BRCA2, and that other dominant breast
cancer susceptibility genes may exist. Linkage analysis of families
negative for BRCAJ and BRCA2 mutations would further support
this philosophy, and we are currently collecting samples from other
family members wherever possible. The finding of BRCAI muta-
tions in only one out of five breast/ovarian cancer families suggests
additional familial ovarian cancer gene(s) also exist. Patients tested
for BRCA1 and BRCA2 mutations and found to be negative should,
thus, be informed ofthe potential ofmutations in other as yet uniden-
tified breast and ovarian cancer susceptibility genes contributing to
continued increased cancer risk.
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